drugset / Trial / NCT00306748
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14 days.
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linaclotide | Peptide | 100 ug | Oral |
| Subject | Linaclotide | Peptide | 300 ug | Oral |
| Subject | Linaclotide | Peptide | 1000 ug | Oral |